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ABSTRACT 
One of the major obstacles to pulmonary-directed gene therapy using adenoviral vectors is the induction of 
inflammation. W e investigated whether the adenoviral particles that constitute the initial inoculum can serve 
as an inflammatory stimulus, independent of their ability to express genes that they contain. Viral particles 
were prepared that are defective in gene expression by (i) isolating particles that have incomplete genomes 
by selecting those that have buoyant densities on CsCl density gradients lighter than complete viruses; and 
(ii) cross-linking viral D N A by exposure to ultraviolet light in the presence of 8-methoxypsoralen. The defec-
tive particles retained their icosahedral appearance when viewed by electron microscopy but lost their plaque-
forming ability on 293 cells. High doses of intact, incomplete, or inactivated viral particles were instilled in-
tratracheally into CBA/J mice, and after 6 days the amount of inflammation was quantified by counting 
inflammatory cells contained vdthin lung tissue. W e found that the inflammatory responses induced by the 
incomplete or inactivated viral vectors were quantitatively similar to those caused by intact, competent viral 
vectors. W e conclude that high doses of adenoviral vectors that are used for gene therapy can induce pul-
monary inflammation, independent of expressing the genes they contain. 
OVERVIEW SUMMARY 
The amount of pulmonary inflammation induced in mice by 
intratracheal administration of high doses of adenoviral 
vectors was compared to that induced by viral particles that 
lack the ability to express the genes that they contain. The 
number of inflammatory cells infiltrating the lung 6 days 
after particle administration was similar between animals 
receiving normal versus defective adenoviral particles. 
INTRODUCTION 
PULMONARY INFLAMMATION comphcates the use of recombi-
nant adenoviruses as gene therapy vectors. Administrating 
high doses of adenoviral vectors to the airways of experimen-
tal animals causes pulmonary infiltrates consisting of 
macrophages and lymphocytes with neutrophils appearing tran-
sientiy during the early stage (Ginsberg et al, 1991; Prince et 
al, 1993; Simon etal, 1993; Brody etal, 1994; Engelhardt et 
al, 1994; Yang et al, 1994; Yei et al, 1994). Pulmonary in-
filtrates have also been reported in a patient who received a rel-
atively high dose of an adenovirus-based vector during a gene 
therapy tiial for treatment of cystic fibrosis (Crystal et al, 
1994). The causes of the pulmonary inflammation induced by 
adenoviral vectors are being actively investigated. Elevated lev-
els of the inflammatory cytokines, interleukin-1 (IL-1), IL-6, 
and tumor necrosis factor-a, have been detected following air-
way administration of either wild-type or recombinant aden-
oviruses (Ginsberg et al, 1991; Crystal et al, 1994). In many 
animal models, the humoral immune system is activated, lead-
ing to generation of antiviral antibodies (Yei et al, 1994; Zabner 
et al, 1994). Cytotoxic T lymphocytes accumulate in the lung 
as part of a ThI response mediated by helper T cells that re-
lease IL-2 and interferon-y (Engelhardt et al, 1994; Yang et 
al, 1994, 1995). Expression of adenovirus-specific genes, de-
spite the deletion of the El region, is thought to provide a stim-
ulus that leads to the immune response. Manipulation of the 
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adenoviral genome that further reduces expression of adenovi-
ral genes has been shown to decrease the pulmonary inflam-
matory reaction (Engelhardt et al, 1994; Yang et al, 1994). 
Although residual expression of viral genes within trans-
fected cells can contribute to the inflammatory response, an im-
portant stimulus may be supphed by the proteins contained in 
the adenoviral particles that serve as vehicles for gene dehv-
ery. In the present study, we determined whether expression of 
adenovirus-specific genes within target cells was required for 
pulmonary inflammation to occur following intiatracheal ad-
ministration. W e did so by comparing the amount of inflam-
mation caused by intact adenoviral vectors with that caused by 
vectors whose gene expression was impaired. For these stud-
ies, w e used an adenoviral vector containing a marker gene con-
sisting of a c D N A for human IL-1 receptor antagonist (IL-lra), 
designated Ad.RSV/L-7ra. The availability of a sensitive and 
specific ELISA for IL-lra protein provided a method to mea-
sure residual gene expression following in vivo delivery of de-
fective viral particles. Importantiy, IL-lra could serve as a 
marker gene because we had previously found that the amount 
of inflammation induced by Ad.RSV/L-ira following intratra-
cheal delivery to mice did not differ from the amount caused 
by a recombinant adenovirus that contained no transgene ex-
pression cassette (McCoy et al, 1995). 
MATERIALS AND METHODS 
Adenoviral vectors 
The construction and characterization of a recombinant ade-
noviral vector containing a human IL-lra c D N A (Ad.RSV/L-
ira) has been previously described by Roessler et al. (1995). 
Ad.RSV/L-/ra has deletions in the E I A and EIB regions (map 
units 1-9), and in the E3 region (map units 83-85) that make 
it replication defective and provide adequate room for insertion 
of an expression cassette. The IL-lra expression cassette, which 
is inserted in the El position, consists ofthe Rous sarcoma virus 
(RSV) long terminal repeat (LTR) as promoter, a c D N A for hu-
man IL-lra, and a transcription termination signal supplied by 
the simian virus-40 late gene polyadenylation sequence. 
Ad.RSV/L-/ra was propagated using the permissive 293 cell 
line and purified from cell lysates by centrifuging twice on CsCl 
density gradients. The band containing intact, complete viral 
particles was removed from the CsCl gradient and desalted on 
Sephadex G50 columns (Pharmacia, Uppsala, Sweden) with 
phosphate-buffered saline (PBS). The viral preparations were 
analyzed for their ability to form plaques on confluent 293 cell 
monolayers (Graham et al, 1977). 
Preparation of incomplete Ad.RSVll^-lra. particles 
Incomplete particles of Ad.RSV IL-lra were isolated from 
the final CsCl density gradient that was used to prepare intact 
Ad.RSV//,-/ra (Buriingham et al, 1974; Toth et al, 1982; 
Morin and Boulanger, 1984). The visible band that formed 
above that containing the complete particles was removed by 
puncturing the lateral wall of the centrifuge tube at the appro-
priate site with an 18-gauge needle. The particle suspension that 
was aspirated from the gradient was desalted on a Sephadex 
G50 column with PBS. 
Inactivation of Ad.RSVlL-lna by psoralen/ultraviolet 
light treatment 
Ultiaviolet light treatment in the presence of 8-methoxypso-
ralen was used to inactivate Ad.RSV/L-/ra (Hudson et al, 
1985; Cotten e/a/., 1992,1994). One miUiliter containing 3.8 X 
10^2 particles of Ad.RSV/L-/ra in P B S was placed into a 35-
m m culture dish at 4°C. 8-Methoxypsoralen (Sigma Chemical 
Co., St. Louis, M O ) was dissolved in dimethylsulfoxide at 33 
mg/ml and added to the viral suspension to yield a final con-
centiation of 330 pg/ml. The plate was placed on a layer of 
chipped ice and exposed to ultiaviolet A band light generated 
by an argon laser (Innova 328, Coherent Inc., Palo Alto, C A ; 
spectial output 333, 351.1, and 363 nm). Light was conducted 
through a fiber optic catheter (Forensic Optical Cable, Coherent 
Inc.) positioned 30 cm above the virus-containing culture dish 
so that the diameter of the beam matched that of the culture 
dish. The sample was exposed for 30 min, resulting in an ul-
traviolet A dose of 180 I/cm^. The plate was rotated periodi-
cally to maintain adequate cooUng and insure even exposure of 
the particles. The inactivated particles were then passed over a 
Sephadex G-50 column that was equilibrated and eluted with 
PBS to remove free psoralen. 
Electron microscopy 
An aliquot of viral particles was fixed in 1% glutaraldehyde, 
0.05 M cacodylate buffer p H 7.4 for 10 min at room tempera-
ture. The solution was spread over 200-mesh carbon-coated 
grids (Electron Microscopy Sciences, Fort Washington, PA). 
After 10 min, excess suspension was wicked off with filter pa-
per. The grids were stained with 2 % uranyl acetate for 1 min, 
rinsed, and allowed to dry. The particles were viewed using a 
Philips CM-10 transmission electron microscope (Eindhoven, 
The Netherlands). 
Detection of adenoviral E2A protein 
by Immunoelectrophoresis 
Monolayers of 293 cells in 60-mm tissue culture dishes were 
rinsed twice with medium and overlaid widi 2 ml of medium 
containing viral particles at 5,000 particles per cell. After 4 hr 
at 37°C in 5 % C02/95% air, the medium was replaced witii 
fresh containing 1 0 % fetal bovine serum. After 20 hr, the cells 
were suspended by scraping, centrifuged at 1,000 X ̂  for 10 
min, and suspended in buffer containing sodium dodecyl sul-
fate and /3-mercaptoethanol. The proteins contained in the 
lysates were separated by electiophoresis on 8 % polyacry-
lamide gels (Laemmli, 1970) and transferred electtophoretically 
to Immobilon-P membranes (Millipore Corp., Bedford, M A ) . 
The membranes were probed widi a mouse monoclonal anti-
body against adenovirus E 2 A protein (clone B6-6-10; gener-
ously provided by Dr. Amold I. Levine, Princeton University, 
Princeton, NI) (Reich et al, 1983). The membranes were de-
veloped using a goat anti-mouse horseradish peroxidase-conju-
gated secondary antibody and a chemiluminescence detection 
system (ECL), both of which were obtained from Amersham 
Life Sciences (Arlington Heights, IL). The molecular weights 
of bands were measured by comparing the distances migrated 
with those of protein standards (New England Biolabs, Beveriy 
MA). 
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Intratracheal administration of viral particles to mice 
Specific pathogen-ft-ee, male, CBA/I mice that were 4-6 
weeks old were purchased from Jackson Laboratories (Bar 
Harbor, M E ) . Each animal was anesthetized inttaperitoneally 
with 0.2 mg/gm ketamine and positioned with its dorsal sur-
face against a board that was tilted 45° to the horizontal with 
its head up. The skin and connective tissue were incised over-
lying the cervical ttachea, and 50 pl of PBS, with or without 
viral particles, was slowly injected intrattacheally using a 
Hamilton syringe (Reno, N V ) . The incision was closed with a 
surgical clip, and the animal retumed to its cage. After 6 days, 
each animal was anesthetized again with ketamine and sacri-
ficed by exsanguination. The lungs were perfused free of blood 
by slowly injecting 3 ml of P B S into the right ventricle with 
the solution being allowed to exit through a vent in the left atrial 
appendage. The ttachea was then cannulated with 1.27-mm di-
ameter tubing and the lungs lavaged with a single 1-ml aUquot 
of PBS. 
Quantification of pulmonary inflammatory cells 
The number of inflammatory cells infilttating the lung tis-
sue was used to quantify the degree of pulmonary inflamma-
tion (Curtis et al, 1994). The excised, perfused lungs were 
minced and incubated for 30 min at 37°C in a solution con-
taining 1.0 mg/ml Type IV collagenase and 50 U/ml DNase I 
(both from Sigma Chemical Co., St. Louis, M O ) in Dulbecco's 
modified Eagle's medium. After digestion, the tissue was me-
chanically disrupted by aspirating and expelUng it 30 times 
through a 10-ml plastic syringe (Becton Dickinson, Rutherford, 
NJ). The cells were centrifuged at 500 X g for 10 min, after 
which contaminating erythrocytes were lysed in NH4CI. 
Finally, the cells were filtered through 100-/im Nytex filters 
(Tetko, Switzerland) and counted in a hemocytometer. 
Flow cytometric analysis of lymphocyte subtypes 
The single-cell suspensions from coUagenase-digested lungs 
were analyzed using an EPICS Elite apparatus (Coulter Corp., 
Hialeah, FL), as previously described (Curtis etal, 1994). Cells 
were stained with the following fluorescein isothiocyanate-la-
beled monoclonal antibodies obtained from PharMingen (San 
Diego, C A ) : 145-2C11, anti-CD3, RM4-5, anti-CD4; 53-6.7, 
anti-CDS; and RA3-6B2, anti-B220. At least 20,000 events 
were collected for each sample. 
IL-lra assay 
Concenttations of human IL-lra in bronchoalveolar lavage 
fluid were determined by an ELISA ( R & D Systems, 
MinneapoUs, M N ) . The lower Umit of detection of the assay 
was 0.03 ng/ml. The reactivity of murine IL-lra is less than 
0.1-0.5% that of human IL-lra. Prior to assay, the bron-
choalveolar lavage fluid was centrifuged at 8,800 X g for 10 
min to remove cells and debris. 
Statistical methods 
Data are expressed as the mean ± S E M . Analysis of vari-
ance was used to test for statistically significant differences be-
tween groups (StatView 4.0, Abacus Concepts Inc., Berkeley, 
C A ) . If differences were present (p < 0.05), pair-wise compar-
isons were performed using Fisher's protected least significant 
different (PLSD) test. 
RESULTS 
Characterization of incomplete and inactivated 
adenoviral particles 
The physical and biological properties of the various prepa-
rations of adenoviral particles were characterized in several 
ways. Transmission electton microscopy was used to assess par-
ticle integrity. As expected, Ad.RSV/L-/ra appeared as ap-
proximately 65-nm icosahedral particles (Fig. 1). Staining with 
uranyl acetate caused the centtal cores of the particles to ap-
pear electron dense. The incomplete particles of lower buoyant 
density had a similar icosahedral shape. The core region of some 
of the particles stained less darkly than the complete particles, 
presumably due to incomplete packaging of core contents. The 
viral particles that had been tteated with psoralen and ultravi-
olet Ught were indistinguishable from untteated adenoviral vec-
tors. 
Infectivities ofthe various adenoviral preparations were mea-
sured using a plaque-forming assay on 293 cells. The particle 
to pfu ratio of intact Ad.RSV/L-/.ra varied sUghtly from prepa-
ration to preparation with a mean of 25.9 ± 9.3 (SEM, n = 6). 
The infectivity of incomplete particles was markedly reduced 
with less that 1 infectious unit detected when up to 3.5 X 1 0 " 
particles were placed onto 293 cell monolayers. Psoralen/ultra-
violet light treatment was very effective at rendering particles 
noninfectious; less than 1 infectious unit in 3.5 X 1 0 " particles 
were found following treatment. 
As a sensitive indicator of viral genome inactivation, the ex-
pression of human IL-lra was measured 6 days following in-
ttattacheal administtation of Ad.RSV/L-/ra. The IL-lra con-
centtation in bronchoalveolar lavage fluid obtained from 
animals receiving 7 X 10'° incomplete viral particles was un-
detectable (<0.03 ng/ml; n = 5), while the IL-lra concentta-
tion in bronchoalveolar lavage fluid collected concurrentiy from 
animals receiving intact Ad.RSV//,-/ra was 4.4 ± 0.8 ng/ml 
(mean ± S E M , n = 3). The ability of psoralen/ulttaviolet light 
tteatment to inactivate Ad.RSV/L-/ra gene expression was also 
tested. The concentration of IL-lra in bronchoalveolar lavage 
fluid obtained from animals receiving 7.0 X 10'° inactivated 
viral particles was undetectable (<0.03 ng/ml, n = 5). Animals 
receiving intact Ad.RSV/L-/ra concurrently had 11.0 ±0.4 
ng/ml (mean ± S E M , n = 5) IL-lra in their lavage fluid. 
W e also determined whether incomplete or inactivated par-
ticles had lost the abiUty to express a virus-specific protein, 
namely the 72-kD E 2 A gene product. Monolayers of 293 ceUs 
were infected with viral particles, and after 24 hr cell lysates 
were analyzed for E 2 A antigen by Immunoelectrophoresis. W e 
found that lysates from cells infected with intact Ad.RSV/L-
ira particles contained easily detectable E 2 A antigen (Fig. 2, 
lanes 1 and 2). Lysates from cells infected with incomplete or 
psoralen/ulttaviolet light-tteated Ad.RSV/L-ira particles failed 
to show a band at — 7 2 k D under assay conditions that would 
have revealed E 2 A antigen at levels down to 1 % of die amount 
generated by intact viral particles. 
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FIG. 2. Immunoelecttophoresis of Ad.RS VIL-Ira-infected 
293 cells for adenoviral E 2 A antigen. Monolayers of 293 cells 
were incubated with viral particles (700 particles/cell). After 
24 hr, lysates were analyzed by Westem blot using a mono-
clonal antibody against the E 2 A adenovims protein. Lane 1, 
Lysate from 10^ cells that had been infected with intact 
Ad.RS VIL-Ira particles; lane 2, same as lane 1 except con-
taining lysate from 10^ cells; lane 3, lysate from 10^ cells ex-
posed to buffer alone; lane 4, lysate from 10^ cells exposed to 
incomplete viral particles; lane 5, lysate from IO' ceUs exposed 
to psoralen/ulttaviolet light-inactivated Ad.RS VIL-Ira parti-
cles. The arrows point out the distances migrated by protein 
standards. 
FIG. 1. Electron photomicrographs of adenoviral particles. 
Intact, incomplete, and inactivated adenoviral preparations were 
prepared as described in Materials and Methods. After fixation 
with glutaraldehyde and staining with uranyl acetate, the parti-
cles were examined in the transmission electton microscope. A. 
Intact Ad.RSVIL.lra particles. B. Incomplete Ad.RSVIL-lra 
particles. C. Psoralen/ulttaviolet-light-treated Ad.RSVIL-lra. 
Bar, 100 nm. 
Inflammation induced by intact, incomplete, or 
inactivated Ad.RSVlL-lrdi 
Intratracheal instillation of Ad.RSViL-ira caused a dose-de-
pendent increase in the number of inflammatory cells released 
from coUagenase-digested lungs (Fig. 3). In a previous study. 
107 108 109 1010 1011 
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FIG. 3. Pulmonary inflammation caused by intact 
Ad.RSVIL-lra. Anesthetized mice were injected inttattacheally 
with 0.05 ml of PBS alone or containing various concenttations 
of intact Ad.RSVIL-lra. After 6 days, die animals were sacri-
ficed, and the number of leukocytes within coUagenase-di-
gested lungs were counted. Data are pooled from four separate 
experiments. Each point represents the mean ± S E M (n = 3-5 
animals) of the number of inflammatory cells in Ad.RSVIL-
Ira-treated lungs expressed as tiie percent of inflammatory cells 
relative to the number present in the lungs of control animals 
receiving PBS concurrently. [*indicates numbers of inflamma-
tory cells per lung tiiat are significantiy higher (p < 0.05) tiian 
that of animals receiving PBS.] 
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we showed that the increase in inflammatory cells was associ-
ated with the histologic appearance of an alveolar infilttate con-
sisting predominantly of lymphocytes and macrophages 
(McCoy et al, 1995). The administtation of high doses (7.0 X 
10'° particles/animal) of incomplete particles also caused a sta-
tistically significant (p < 0.01) increase in lung inflammatory 
cells relative to animals receiving PBS (Fig. 4). Importantly, 
there was no difference in the number of lung inflammatory 
cells released from the lungs of animals receiving intact and in-
complete Ad.RSV/L-/ra (p = 0.49, n = 4-5). The distiibution 
of lymphocytes, monocytes, and neuttophils within the popu-
lation of lung inflammatory cells was determined for each group 
of animals by examining cells that had been sedimented onto 
sUdes by cytocentrifuge and stained with a modified Wright's 
stain. W e found no significant difference (p > 0.1) in the dis-
tribution of inflammatory cell types obtained from lungs of an-
imals tteated with PBS alone, with intact functional vectors, or 
with incomplete particles. The percentages of cells from the 
combined groups were 71.3% lymphocytes, 22.1% mono-
cyte/macrophages, and 6.6% neuttophils. 
W e also measured the amount of inflammation caused by ade-
noviral particles that had been previously inactivated by pso-
ralen/ulttaviolet Ught tteatment. Similar to the results using in-
complete particles, we found no difference in the number of 
inflammatory ceUs released from coUagenase-digested lungs that 
had been tteated with either intact or inactivated Ad.RSV/L-ira 
particles (p = 0.69, n = 5). Importantiy, both preparations of par-
ticles caused a statistically significant increase (p < 0.01) in lung 
inflammatory ceUs over lungs receiving PBS alone (Fig. 5). 
Identification of lymphocyte subsets infiltrating the 
lungs of animals receiving incomplete or intact 
AdRSVlL-lia 
Although the total number of inflammatory cells infiltrating 




FIG. 4. Comparison of pulmonary inflammation caused by 
intact and incomplete Ad.RSVIL = Ira. Anesthetized mice 
were given 0.05 ml of PBS alone (n = 5) or with 7.0 X 10'° 
particles of intact (n = 4) or incomplete (n = 5) Ad.RSVIL-
lra. After 6 days, the animals were sacrificed, and the number 
of inflammatory ceUs contained in coUagenase-digested lungs 
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FIG. 5. Comparison of pulmonary inflammation caused by 
intact and inactivated Ad.RSVIL-lra. Anesthetized mice were 
given 0.05 ml of PBS alone or with 7.0 X 10'° particles of in-
tact or psoralen/ultraviolet light-inactivated (psoralen/uv) 
Ad.RSVIL-lra. After 6 days, the animals were sacrificed, and 
the number of inflammatory cells contained in coUagenase-di-
gested lungs were counted. Data represent the mean ± SEM, 
n = 5. 
or intact Ad.RSV/L-/ra, we investigated whether the relative 
proportions of lymphocyte subsets might differ. Accordingly, 
flow cytometry with fluorescein-labeled antibodies was used to 
analyze the number of lymphocytes displaying the cell-surface 
antigens CD3, CD4, CDS, and B220. W e found negligible dif-
ferences in the proportions of lymphocyte subtypes obtained 
from animals receiving intact or incomplete adenoviral parti-
cles (Table 1). A quantitatively smaU, but statistically signifi-
cant (p = 0.03), increase in the percentage of B cells (B220-I-) 
was seen in animals receiving incomplete viral particles com-
pared to those administered intact Ad.RSV/L-ira. No other sta-
tistically significant differences were present. 
Table 1. Lymphocyte Subsets Within Lltngs of Mice 
Infected with Incomplete and Intact Ad.RSVIL-Ira 
Ad.RSVlL-lra 
Lymphocyte subtype PBS^ Intact Incomplete 
CD3+ (T ceUs) 
CD4+ 
CD8+ 
B220+ (B cells) 
49 ±3 
33 ± 1 
14 ±2 
51 ±2 
41 ± l*" 
27 ± 1'' 
10 ± 1 
47 ±2'= 
41 ±2'' 
28 ± l*" 
14 ±2 
53 ± P 
^% of total lymphocytes. 
^p < 0.05 compared to PBS. 
'̂ p = 0.03 comparing intact and incomplete Ad.RSVIL-lra. 
A total of 50 pl of P B S alone or containing 4.9 X 10' par-
ticles of intact or incomplete Ad.RSVIL-lra were inttatta-
cheally instilled into mice. After 6 days, the animals were sac-
rificed and their inttapulmonary mononuclear inflammatory 
cells recovered and analyzed by flow cytometry. Each entry in 
the table represents the mean ± S E M (n = 3) of the percent of 
total lymphocytes stained by the respective antibody. 
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DISCUSSION 
Use of adenovims-based gene therapy vectors has proved to 
be one of the more efficient, currentiy available methods for 
ttansferring genes to nondividing cells in vivo (Levrero et al, 
1991; Rosenfeld et al, 1992; Engelhardt et al, 1993; Zabner 
et al, 1993). However, a limitation to the use of high doses of 
adenoviral vectors for the lung has been the development of 
pulmonary inflammation (Simon et al, 1993; Brody et al, 
1994; Crystal et al, 1994; Engelhardt et al, 1994; Yang et al, 
1994; Yei et al, 1994). The mechanisms by which adenoviral 
vectors induce inflammation are likely to be multiple and com-
plex. W e chose to approach the problem by examining the con-
tribution of the viral particle itself, independent of its ability to 
express the genes it contains. W e found that the development 
of pulmonary inflammation in mice receiving adenoviral vec-
tors did not require a functional viral genome. 
W e used two different methods to generate viral particles 
that were defective in gene expression. A class of particles are 
made during adenoviral production in 293 cells that contain an 
incomplete complement of D N A (Buriingham etal, 1974; Toth 
et al, 1982; Morin and Boulanger, 1984). These particles can 
be separated from complete virions by sedimentation on CsCl 
gradients due to their lighter buoyant densities. W e found that 
incomplete particles of Ad.RSV/L-ira retained their icosahe-
dral shape, but were unable to replicate or express the E 2 A ade-
noviral protein in 293 cells. Importantiy, these particles failed 
to induce expression of human IL-lra when deUvered to mouse 
lungs. It is highly unlikely that these incomplete particles could 
induce in vivo synthesis of adenovims-specific genes for two 
reasons. First, the adenoviral genome, which is a single, linear, 
double-sttanded D N A molecule, is packaged into the viral cap-
sid with its left end being incorporated first (Hammarskjold and 
Winberg, 1980). Because the IL-lra transgene is located very 
close to the left end of the adenoviral genome (replaces map 
units 1-9), all adenovims-specific stmctural genes are therefore 
located to the right of it. For this reason, incomplete particles 
that did not induce IL-lra expression in mouse lungs could not 
have packaged and expressed vims-specific genes without pro-
ducing IL-lra. Further evidence that the incomplete particles 
were deficient in gene expression was our observation that they 
failed to produce E 2 A in the permissive 293 cell line. 
Although the adenoviral particles of lighter buoyant density 
retained their capsid geometry when viewed in transmission 
electron micrographs, it is known that some of their stmctural 
proteins are incompletely assembled or processed (Morin and 
Boulanger, 1984). The final steps of viral assembly involve pro-
teolytic cleavage of capsid proteins, a process that is not nec-
essarily complete in the lighter particles. Therefore, it is possi-
ble that these incomplete particles do not precisely duplicate 
the inflammatory properties of intact, infectious virions. 
Accordingly, w e used a second method, namely cross-Unking 
of viral D N A by exposure to ultraviolet light in the presence of 
8-methoxypsoralen, to generate particles having defective gene 
expression. Previous studies by others have shown that tteat-
ment of adenovimses with psoralen/ultraviolet light blocks vi-
ral replication but leaves intact their ability to enter target cells 
and induce endosomolysis (Cotten et at., 1994). These studies 
also have shown that viral gene transcription, as measured by 
reverse transcriptase-polymerase chain reaction, was prevented 
by psoralen/ulttaviolet light treatment. In agreement, w e found 
that human IL-lra levels were undetectable in bronchoalveolar 
lavage fluid from mice receiving psoralen/ulttaviolet light-in-
activated Ad.RSV/L-ira. Because D N A cross-links formed by 
psoralen/ulttaviolet light tteatment are evenly distributed along 
the adenoviral genome (Cotten et al, 1994), it is very unlikely 
that the inactivated Ad.RSVIL-lra could express substantial 
levels of vhus-specific genes without also expressing similar 
levels of IL-lra. This conclusion is further supported by our ob-
servation that inactivated particles did not produce E 2 A in cul-
tured 293 cells. 
Despite these considerations, w e cannot exclude the possi-
biUty that a small number of competent viral particles were con-
tained in the preparations of incomplete or inactivated 
Ad.RSViL-ira. However, the extent of inflammation seen in 
the animals receiving these preparations is very unlikely to be 
due to residual active particles. The IL-lra ELISA has a lower 
limit of detection of 0.03 ng/ml. Because IL-lra levels in mice 
receiving intact, active Ad.RSViL-ira ranged from 4.4 to 11.0 
ng/ml, the maximal amount of residual gene expression in an-
imals receiving defective vims was less than 0.3-0.7% of the 
level expressed in animals receiving intact vims. The relation-
ship between the dose of intact Ad.RSViL-ira and the number 
of lung inflammatory cells (Fig. 3) shows that animals receiv-
ing less than 10' intact particles do not develop increased lev-
els of pulmonary inflammatory cells. Therefore, even if 
0.3-0.7% of the particles contained in the inocula of incom-
plete or inactivated vectors were functionally active, there was 
an insufficient number of competent particles to account for the 
amount of inflammation observed (Figs. 4 and 5). 
In addition to finding no difference in the number of in-
flammatory cells within the lungs of animals receiving intact, 
incomplete, or inactive viral particles, w e also found no sig-
nificant differences in the distribution of inflammatory cell 
types. Lymphocytes and macrophages increased proportion-
ally, with neutrophils remaining the minor component. These 
findings correlate well with published descriptions of lung his-
tology following adenovims administration (Ginsberg et al, 
1991; Prince et al, 1993; Simon et al, 1993; Brody et al, 
1994; Engelhardt et al, 1994; Yang et al, 1994; Yei et al, 
1994). Our analysis of lymphocyte subsets showed that the 
percentage of lymphocytes that were CDS"*" was similar be-
tween active and incomplete viral particles. One stimulus that 
is known to initiate a cytotoxic T cell response is the display 
of endogenously synthesized viral peptides on the surface of 
infected cells in conjunction with class I major histocompat-
ibility antigens. However, the presence of a CDS"^ infiltrate 
in mice that received incomplete particles does not imply that 
viral gene synthesis had taken place. In fact, there is another 
class 1-dependent pathway leading to C D 8 + cell accumulation 
that does not require synthesis of foreign proteins (Kaufmann, 
1988). This alternative pathway, which involves the uptake 
and processing of exogenous foreign material by antigen-pre-
senting cells, may be responsible for the C D 8 + infiltrate seen 
in our animals. 
Our finding that high doses of expression-defective aden-
oviral particles can induce inflammation has several important 
implications regarding the use of adenoviral vectors in pul-
monary-directed gene therapy. First, manipulations of the ade-
noviral genome that limit expression of vims-specific genes will 
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not prevent lung inflammation when high doses of vims are 
used. The dose-response curve for airway delivery of genes by 
adenoviral vectors is uncertain. Zabner and colleagues instilled 
an adenoviral vector containing the cystic fibrosis ttansmem-
brane conductance regulator (CFTR) c D N A into the noses of 
cystic fibrosis patients (Zabner et al, 1993). They reported that 
exposure of 0.5 cm^ of nasal epithelium to as low as 10* in-
fectious units temporarily normalized transepithelial electro-
physiology without causing inflammation. Crystal et al. re-
ported that airway administtation of 2 X 10* pfu of a 
CFTR-containing adenoviral vector induced expression of 
C F T R protein in bronchial epithelial cells (Crystal et al, 1994). 
However, other patients participating in this stiidy failed to 
demonsttate C F T R protein in bronchial lining cells despite re-
ceiving a 10-fold higher dose. Furthermore, a patient who re-
ceived the highest dose of vims in the study, 2 X 10' pfu, 
acutely developed pulmonary inflammation. 
Other investigators have reported that adenoviral vectors 
have a low efficiency for ttansferring genes into intact human 
airways. In particular, G m b b and colleagues exposed excised 
segments of human bronchi to adenoviral vectors and measured 
the amount of ttansgene expression (Gmbb et al, 1994). They 
found only low levels of gene expression despite using up to 
4 X 1 0 " pfu/ml of vector. The only significant expression oc-
curred within basal epithelial cells in areas of the airway that 
had been previously abraded. In parallel experiments, these in-
vestigators found a similarly low efficiency of gene transfer in 
mice. Of considerable concem is our observation that the higher 
doses of vector used by G m b b and coUeagues are in the same 
range or higher than those that we found induced inflammation 
in mice. Thus, the inflammatory response to the viral particle 
itself might present a dose-Umiting toxicity. 
In summary, we found that high doses of adenovhal vectors 
can induce pulmonary inflammation, independent of their ca-
pacity to express the genes which they contain. This result sug-
gests that manipulation of the adenoviral genome to Umit ex-
pression of viras-specific genes will not prevent lung 
inflammation if high doses of adenovims vectors are required 
to achieve therapeutic gene transfer. There wUl likely be an up-
per Umit to the viral dose, above which inflammation will be 
induced solely by the presence of the viral proteins contained 
within the inoculum. The successful use of adenoviral vectors 
for pulmonary gene therapy will depend upon their ability to 
achieve adequate gene ttansfer at doses below those that induce 
particle-dependent inflammation. Altematively, methods will 
have to be developed that block the inflammatory response gen-
erated by the viral capsid proteins. 
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